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The spread of antibiotic resistance amongst bacterial pathogens has led to an urgent
need for new antimicrobial compounds with novel modes of action that minimize the
potential for drug resistance. To date, the development of new antimicrobial drugs is
still lagging far behind the rising demand, partly owing to the absence of an effective
screening platform. Over the last decade, the nematode Caenorhabditis elegans
has been incorporated as a whole animal screening platform for antimicrobials. This
development is taking advantage of the vast knowledge on worm physiology and how it
interacts with bacterial and fungal pathogens. In addition to allowing for in vivo selection
of compounds with promising anti-microbial properties, the whole animal C. elegans
screening system has also permitted the discovery of novel compounds targeting
infection processes that only manifest during the course of pathogen infection of the
host. Another advantage of using C. elegans in the search for new antimicrobials is that
the worm itself is a source of potential antimicrobial effectors which constitute part of its
immune defense response to thwart infections. This has led to the evaluation of effector
molecules, particularly antimicrobial proteins and peptides (APPs), as candidates for
further development as therapeutic agents. In this review, we provide an overview on
use of the C. elegans model for identification of novel anti-infectives. We highlight some
highly potential lead compounds obtained from C. elegans-based screens, particularly
those that target bacterial virulence or host defense to eradicate infections, a mechanism
distinct from the action of conventional antibiotics. We also review the prospect of using
C. elegans APPs as an antimicrobial strategy to treat infections.
Keywords: Caenorhabditis elegans, antimicrobials, anti-virulence, immunomodulator, antimicrobial peptides
INTRODUCTION
It is undeniable that antibiotics have had an enormous impact on global human health by drastically
reducing infection-associated mortality. Nonetheless, the abuse and uncontrolled use of antibiotics
has resulted in the emergence and spread of resistant bacteria. Whilst resistance to antibiotics
has escalated steadily, the number of new antimicrobial drugs approved, especially those with
novel modes of action, continues to decline (Boucher et al., 2013). Among the vast number
of Gram-positive and Gram-negative bacteria, the ‘ESKAPE’ group of pathogens (Enterococcus
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas
aeruginosa, and Enterobacter species) represent the most common antibiotic-resistance pathogens
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(Pendleton et al., 2013). The emergence of variant pathogens such
as the New Delhi metallo-ß-lactamase 1 (NDM-1)-producing
Enterobacteriaceae strains (Kumarasamy et al., 2010) and
colistin-resistant Escherichia coli harboring the mcr-1 gene (Liu
et al., 2016; McGann et al., 2016) have exacerbated the situation
and further underscores the importance of new innovative anti-
infective strategies to minimize the spread of drug resistance.
A major obstacle in the identification of effective anti-infective
therapies is the absence of efficient in vivo screening platforms.
Since the first introduction of Caenorhabditis elegans to study
developmental biology, the worm has proven to be a versatile host
model for elucidating molecular and cellular aspects of various
infectious diseases. C. elegans has been adopted as an in vivo
infection model to dissect the intricate host–pathogen interaction
and the evolutionarily conserved mechanisms employed by
pathogens to infect and kill the host (Ermolaeva and Schumacher,
2014; Cohen and Troemel, 2015). The descriptions of an
expanding list of bacterial and fungal pathogen infections in
C. elegans (Marsh and May, 2012) have led to the use of worms
as a whole organism system for antimicrobial and anti-infective
drug discovery. This review will assess the use of C. elegans
as a platform for the discovery of novel anti-infectives or
antimicrobial compounds that target bacterial virulence or host
immune responses to attenuate infections. We also highlight the
potential of C. elegans as a rich source of antimicrobial proteins
and peptides (APPs), key components of innate immunity.
C. elegans PLATFORM FOR
ANTI-INFECTIVES DISCOVERY: WHY
AND HOW?
The increasing popularity of C. elegans as a host model
is attributed to its small (∼1 mm) and simple anatomy,
short generation time, high fecundity, fully sequenced genome
(∼100 Mb) and the relatively easy and inexpensive maintenance.
Moreover, working with the worm offers great advantage as many
resources of genetic and genomic knowledge and techniques are
available to facilitate experimental manipulation (Antoshechkin
and Sternberg, 2007). For example, knocking down worm
genes can easily be achieved through RNA interference (RNAi)
simply by feeding the worms with bacteria harboring a plasmid
engineered to express double-stranded RNA (dsRNA) targeting
the gene of interest. Two RNAi clone libraries covering almost
94% of the 20 000 genes in C. elegans are available and this
allows genome-wide RNAi screens to be performed (Kamath
and Ahringer, 2003; Rual et al., 2004). Furthermore, over
3000 phenotypically defined mutant strains are available from
the Caenorhabditis Genetics Centre. In addition, the worm is
transparent, allowing for in vivo monitoring of cells and the
visualization of fluorescently tagged bacterial and host genes
and proteins throughout the entire course of an experiment.
The nematode defense system is highly homologous to at least
three mammalian conserved innate immunity signaling pathways
which are crucial for defense against pathogens; the p38 Mitogen-
Activated Protein Kinase (p38 MAPK) pathway (Troemel et al.,
2006), the Insulin/Growth Factor-1 (IIS) pathway (Garsin et al.,
2003) and the Transforming Growth Factor-β (TGF-β) pathway
(Mallo et al., 2002). Studies have also indicated that many of
the virulence factors involved in the killing of worms were also
required for the pathogenesis of mammals (Tan et al., 1999; Sifri
et al., 2003) and hence, over the last decade, the utility of the
worm has also been extended to facilitate novel antimicrobial
drug discovery and development (Ewbank and Zugasti, 2011;
Arvanitis et al., 2013). Taken together, these advantages make
C. elegans an ideal model organism in various aspects of biology.
The traditional pipeline for antimicrobial drug discovery
usually begins with in vitro screening of test compounds followed
by subjecting potential hits to in vivo animal testing (Brown
and Wright, 2016). However, these potential compounds often
end up exhibiting poor pharmacokinetic activities and/or are
highly toxic when tested in vivo in animals. Another approach
is to directly determine the in vivo effects of the test compounds
in conventional mammalian models but this approach presents
with serious limitations, including high cost, laborious and
time-consuming procedures and ethical constraints (Arvanitis
et al., 2013). While mammalian models have been utilized
to study potentially new drug leads, screening of a large
number of compounds is prohibited with these models. Both
these approaches have shortcomings and cause significant delay
in antimicrobial discovery. To overcome these limitations,
an alternative method is to conduct the initial testing of
compounds in the C. elegans whole animal system. Exposing
worms to both pathogen and test compounds and subsequently
monitoring worm survival throughout the assay can be easily
performed as an antimicrobial screen of test compounds in
C. elegans. Compounds with potential antimicrobial activity
will contribute to prolonged infected worm lifespan when
compared to the untreated infected worms. Screening of
compounds with the C. elegans whole animal model also allows
preliminary assessment of drug toxicity as worms treated with
these compounds will show similar or decreased survival when
compared to the untreated control (Moy et al., 2009). A further
advantage of the C. elegans model is the self-fertilization of
hermaphrodite worms which allows for cost effective rapid
cultivation of a large population of worms for drug testing
without any of the ethical constraints normally encountered
when working with rodents and primates. The worm is also
amenable to fully automated high-throughput screening whereby
100s of animals can be systematically dispensed into wells of
standard 96- and 384- well plates permitting the screen of larger
compound libraries, the incorporation of fluorescent dye to ease
scoring of dead and alive worms as well as the use of sophisticated
hardware and software for image capturing and data analysis
(Wahlby et al., 2012; Conery et al., 2014). To increase the
efficiency of the high-throughput screen, improvements to the
automated worm sorting and transfer technologies, imaging
and software for data analysis are constantly being undertaken
(O’Reilly et al., 2014).
Another significant advantage of using C. elegans in the
search for new antimicrobial compounds is that, as an in vivo
model, it allows for the detection of compounds that may not
directly target the pathogen viability but instead, may alter
pathogen virulence or enhance the host immune response. Since
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the primary innate immunity signaling pathways identified in
C. elegans are highly conserved evolutionarily, the findings
from the screen may also be extended to higher organisms,
including humans. Nevertheless, although the nematode is a
powerful tool to screen for antimicrobials, it cannot completely
replace mammalian models and certain limitations must be
acknowledged. Firstly, in the laboratory, C. elegans are routinely
cultured at 16, 20, or 25◦C. The worms cannot grow at 37◦C
and this restricts the range of pathogens that can be studied.
Furthermore, C. elegans also has an efficient detoxification
system, which limits the capacity to identify compounds that act
via modulation of host defenses (Ewbank and Zugasti, 2011).
That being said, the use of C. elegans in drug discovery still holds
promise and should be pursued.
IDENTIFICATION OF NOVEL
ANTI-INFECTIVES
Generally, an anti-infective is an agent capable of preventing or
counteracting infection, either by inhibiting the dissemination
of an infectious agent or by killing the pathogen directly.
Antibiotics are one of the well-known examples of anti-infective
agents. Antimicrobial agents have been classified based on their
ability to either kill the bacteria (bactericidal) or inhibit bacterial
propagation (bacteriostatic) by targeting function essential to
bacterial viability. Although these strategies are highly effective
in eliminating the bacteria, they result in substantial stress on
the target bacterium, leading to rapid selection of resistant sub-
populations. Non-antimicrobial approaches to treat infections
are therefore needed as alternative therapies to overcome the
pitfalls of antibiotic resistance. Anti-infectives that do not affect
microbial cell viability, but may instead interfere with virulence-
mediated pathways in pathogens, appear as a new therapeutic
paradigm (Allen et al., 2014). From the host perspective, selective
modulation of the host innate immunity is another emerging
concept driven by advances in the current understanding of host
defense systems (Nijnik, 2013). Conventional in vitro cell-culture
based assays are less likely to probe anti-infectives that target
bacterial virulence or host immunity due to the absence of an
intact and complex host–pathogen relationship. Following the
wide application of C. elegans in infectious diseases modeling,
this tiny nematode has emerged as a very useful model for anti-
infectives drug discovery and development (Desalermos et al.,
2011; Ewbank and Zugasti, 2011). In addition to its ability to
identify novel antimicrobials that impair bacterial growth, the
simple C. elegans model also presents an advantage, as we are
able to select potential anti-virulence and immunomodulatory
molecules in the context of a live animal. The possible outcomes
of a C. elegans-based anti-infective screen are illustrated in
Figure 1.
Compounds with In vivo Antimicrobial
Activity
In the first antimicrobial screen using C. elegans, the standard
agar-based infection assay was modified to form a liquid-based
curing assay in a 96-well plate format for high-throughput
screening of 6,000 individually synthesized molecules and 1,136
natural extracts, consisting mainly of plant and marine extracts,
for their ability to rescue C. elegans following an Enterococcus
faecalis persistent infection (Moy et al., 2006). This screen
identified 16 synthetic compounds and nine natural extracts
that promote survival of E. faecalis infected worms. From
the antimicrobial test, 7 of the 16 compounds inhibited the
replication of E. faecalis in vitro with minimum inhibitory
concentrations (MICs) <31 µg/mL. The screen was refined to a
fully automated process which scaled up the throughput of the
screen from ∼7000 compounds to ∼37,000 unique molecules
and natural product extracts. This allowed the identification of
80 antimicrobial agents that cured C. elegans from a E. faecalis
infection, including 62 known antibiotics and 18 candidates with
previously reported antibacterial effect or structural analogs of
known antibiotics (Moy et al., 2009).
The initial study by Moy et al. (2009) prompted other
initiatives to search for novel anti-infectives and these efforts
have been fruitful. To identify novel therapeutic molecules
toward S. aureus, our group developed a C. elegans–S. aureus
screening platform to perform small-scale in vivo screens on
extracts from plant and marine resources as well as synthetic
molecules (Kong et al., 2014b). In contrast to E. faecalis
that persists in the C. elegans intestinal tract, S. aureus
infection of worms is transient (Sifri et al., 2003). By constant
exposure of C. elegans to S. aureus in liquid medium, 70
candidates were subjected to the C. elegans–S. aureus screen
and 28 positive hits (14 extracts and 14 compounds) were
obtained. Of the 14 natural extracts, 7 of them demonstrated
potential antimicrobial effect against S. aureus when tested
in a standard MIC microdilution assay. Among the most
effective antimicrobial candidates were the extract from Curcuma
longa and its main active component, curcumin (Kong et al.,
2014b). An automated high-throughput C. elegans antimicrobial
screen was used to screen a compound library comprising of
640 FDA-approved drugs for novel antimicrobial molecules
against methicillin-resistant S. aureus (MRSA) (Rajamuthiah
et al., 2014). Of note, closantel, the drug used to eradicate
helminths, was identified as a promising hit that significantly
prolonged the survival of MRSA-infected C. elegans. In vitro MIC
microdilution tests showed that closantel exerted antibacterial
activity against a wide range of Gram-positive and Gram-
negative bacteria at low effective concentrations. Interestingly,
closantel was also effective against the vancomycin-resistant
S. aureus (VRSA) with an MIC of 0.78 µg/mL. The compound
library also contained some clinically relevant antibiotics and
almost all of the antibiotics that were previously known to
be effective against MRSA were also identified as positive hits
in the screen, further validating the robustness of the screen
in detecting highly potential anti-staphylococcal molecules for
future therapeutics development (Rajamuthiah et al., 2014).
Following this, the screen has been expanded to two other
compound libraries consisting of 85,000 compounds (Kim W.
et al., 2015) and ∼21,000 compounds (Rajamuthiah et al.,
2015), respectively. One positive hit from the screen was 1-
Hexadecyl-2-methyl-3-(phenylmethyl)-1H-imidazolium iodide
(NH125), an antibiotic with well-characterized mode of action
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FIGURE 1 | Schematic diagram illustrating the possible outcomes of a Caenorhabditis elegans-based anti-infective screen. From a screen, the
compounds can be categorized as those with possible toxic effect, potential anti-infective effect or no effect. The hits that promote the survival of C. elegans
following an infection can either act as anti-microbial, anti-virulence, or immunoactivator/immunomodulator. The toxic effect of a compound can be further validated
by exposing the worms to the particular compound in an uninfected condition where the worms are fed with dead Escherichia coli OP50.
(Yamamoto et al., 2000). A further study revealed that
NH125 was also able to kill persister cells and eradicate the
formation of MRSA biofilm by penetrating the extracellular
polymeric substance (EPS) matrix within an established biofilm
(Kim W. et al., 2015). Additionally, a novel antibacterial
compound, 3-(phenylsulfonyl)-2-pyrazinecarbonitrile (PSPC),
rescued MRSA-infected worms. PSPC and its derivatives
displayed high antibacterial efficacy toward Gram-positive
bacteria, with higher MIC values observed against Gram-negative
pathogens (Rajamuthiah et al., 2015). Yang et al. (2013) developed
a simple, time-efficient and cost-effective integrated microfluidic-
based C. elegans screening system to test the in vivo antimicrobial
effect of various natural compounds. The three major active
components of the natural product rhubarb (emodin, rhein, and
aloe-emodin) enhanced the survival of worms challenged with
S. aureus and inhibited S. aureus replication at ≤16 µg/mL but
were toxic to the animals at concentrations >60 µg/mL (Yang
et al., 2013).
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A C. elegans–P. aeruginosa liquid-based slow-killing assay
was used to perform an in vivo screen for potential anti-
infective substances against multidrug-resistant P. aeruginosa.
Screening a collection of 1,300 natural extracts mainly consisting
of secondary metabolites from fungal endophytes of medicinal
plants, led to the discovery of four extracts from four different
fungal species with both in vivo and in vitro antimicrobial activity
(Zhou et al., 2011). The in vivo activity and efficacy of naturally
occurring antimicrobial peptides isolated from frog skin were
also evaluated using a C. elegans infection model (Uccelletti
et al., 2010). The peptides, temporin-1Tb and esculentin (1–18),
promoted the survival of P. aeruginosa-infected worms. Exposure
to the peptides for 24 h significantly reduced the intestinal
bacterial load in worms pre-infected with P. aeruginosa. Taking
advantage of the transparent nature of C. elegans, the in vivo
effect of the peptides on membrane permeability was examined
by firstly exposing the P. aeruginosa infected nematodes to
Sytox Green followed by treatment with the peptides and
subsequently, observation of fluorescence intensity within the
intestine of C. elegans. The enhanced fluorescence intensity in
treated infected nematodes indicated that the peptide killed
P. aeruginosa in vivo by permeating the bacterial membrane. The
findings from this study reinforced the fact that C. elegans can
be used to investigate the in vivo mode of action of antimicrobial
molecules within the context of a living animal.
The high-throughput C. elegans screening platform has been
expanded to identify potential antimicrobial therapeutics against
other pathogens that cause clinically significant morbidity and
mortality such as Burkholderia pseudomallei (Lakshmanan et al.,
2014) and A. baumannii (Jayamani et al., 2015). Lakshmanan
et al. (2014) described a robust C. elegans based high-throughput
screen to search for novel antibiotics to treat melioidosis, a highly
lethal infection caused by the Gram-negative B. pseudomallei. As
B. pseudomallei is a Tier-1 organism, a closely related species,
Burkholderia thailandensis, was substituted as the surrogate
pathogen in the screen. One of the hits identified from the
pilot screen of ∼30,000 compounds was Clinafloxacin, a fourth
generation fluoroquinolone antibiotic, which demonstrated
diverse antibacterial activity against B. pseudomallei as well as
other Gram-negative pathogens (Lakshmanan et al., 2014). The
ability of A. baumannii to infect and kill C. elegans led to
the development of a C. elegans–A. baumannii liquid infection
assay to screen for potential anti-A. baumannii agents from
a collection of synthetic insect-derived antimicrobial peptides.
A promising hit was the antimicrobial peptide, cecropin A,
isolated from the mosquito Aedes aegypti. Further analysis
suggested that this peptide exerted its antimicrobial activity
by disrupting the bacterial membrane, leading to cell lysis
(Jayamani et al., 2015). The in vivo antimicrobial effect of small
molecules identified from an in vitro growth inhibition assay was
evaluated using a C. elegans–Burkholderia cenocepacia infection
model. Identification of a compound with good in vitro activity
without curing B. cenocepacia-infected nematodes from infection
highlights the importance of using a live animal model for the
discovery of antimicrobial compounds with promising in vivo
efficacy (Selin et al., 2015). Other drugs and natural compounds
that have been tested for their in vivo antimicrobial properties in
the worm model are listed in Table 1.
Compounds Targeting Bacterial
Virulence
In the first antimicrobial screen by Moy et al. (2006) the
identification of hits that did not interfere with bacterial growth
in vitro or hits with a lower effective concentration in vivo
suggests that these compounds and extracts may either act by
enhancing host immunity or altering pathogen virulence. The
findings from this study also offer proof-of-concept that the
C. elegans whole-animal antimicrobial screening platform is able
to detect hits that may be missed in a conventional cell-culture
based in vitro screen where the live host–pathogen relationship
is absent (Moy et al., 2006). In addition to novel antimicrobial
compounds, the automated high-throughput C. elegans screen
by Moy et al. also identified potential anti-virulence compounds
(Moy et al., 2009), including analogs of small molecules that were
found to prevent P. aeruginosa biofilm development in another
anti-biofilm screen (Junker and Clardy, 2007).
In an earlier study on the effect of compounds on bacterial
virulence, the effect of salicylic acid, a type of phenolic compound
TABLE 1 | Additional drugs/compounds evaluated for in vivo antimicrobial effects using a Caenorhabditis elegans model.
Drugs/compounds Description Infection model Reference
Celecoxib An FDA-approved non-steroidal anti-inflammatory
drug that blocks the COX-2 enzyme. It is used to
relieve fever, pain and inflammation.
C. elegans – MRSA Thangamani et al., 2015
Lamotrigine An FDA-approved anticonvulsant drug that also
inhibits ribosome biogenesis in bacteria, thereby
preventing the growth of bacteria.
C. elegans–Salmonella enterica Stokes et al., 2015
Auranofin A form of gold complex that is mainly implicated in
the treatment of rheumatoid arthritis.
C. elegans–S. aureus Fuchs et al., 2016
Artilysins A modified form of endolysins, enzymes produced
by bacteriophages to hydrolyze the bacterial cell
wall, with improved outer membrane-penetrating
capability.
C. elegans–P. aeruginosa Briers et al., 2014
Berberine derivatives Berberine is a natural alkaloid found in plants. C. elegans–E. faecalis
C. elegans – MRSA
Tomkiewicz et al., 2010
Dolla et al., 2015
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produced naturally by plants, was tested on P. aeruginosa
virulence in the worm model as well as the Arabidopsis thaliana
plant model. Feeding the worms with salicylic acid-treated
P. aeruginosa prolonged worm survival compared to the worms
exposed to untreated bacteria. Microarray and biochemical
analyses proposed that this compound reduced the virulence of
P. aeruginosa by inhibiting the production of biofilm, pyocyanin,
protease, and elastase (Prithiviraj et al., 2005). Following this,
the anti-virulence potential of extracts from three medicinal
plants (Conocarpus erectus, Callistemon viminalis, and Bucida
buceras) was assessed against P. aeruginosa using the C. elegans
paralytic killing, fast-killing and slow-killing models. These
extracts were known to affect bacterial quorum sensing (Adonizio
et al., 2008a). Addition of the individual extracts into the solid
agar medium significantly delayed the killing of nematodes
by P. aeruginosa to a rate similar to worms fed with the
P. aeruginosa lasR quorum sensing mutant, suggesting that
these extracts most likely targeted the bacterial quorum sensing
pathway (Adonizio et al., 2008b). A similar approach was also
used to elucidate the anti-virulence properties of curcumin,
the main bioactive component present in turmeric. Curcumin
rescued C. elegans from a P. aeruginosa (PAO1) infection via
the inhibition of various virulence factors, including pyocyanin,
biofilm, acyl homoserine lactone, and bacterial quorum sensing
(Rudrappa and Bais, 2008). In addition to its anti-virulence
effect on P. aeruginosa, curcumin is also able to rescue worms
from a B. pseudomallei-inflicted infection. We showed that
curcumin interfered with B. pseudomallei iron acquisition and
also inhibited the production of B. pseudomallei lipase, protease
as well as biofilm without affecting bacterial viability. This
suggests the potential of curcumin as an alternative therapy for
the highly lethal melioidosis caused by B. pseudomallei (Eng
and Nathan, 2015). In a recent study, curcumin was reported
to interfere with bacterial virulence in a mouse model of lung
infection, providing an independent validation of the anti-
virulence effect identified in a C. elegans model (Wang et al.,
2016).
Quorum sensing is a complicated cell-to-cell communication
system that regulates the expression of various key virulence
factors in Gram-positive and Gram-negative bacteria, making it
a target of interest for anti-virulence therapy. The P. aeruginosa
quorum sensing system utilizes acyl homoserine lactones as
autoinducer molecules to regulate and direct the expression of
virulence and biofilm-associated genes (Williams et al., 2007).
Other natural inhibitors that have been tested for their anti-
virulence effect in vivo using the C. elegans–P. aeruginosa
infection model are the methanolic extract of Terminalia chebula
fruit (Sarabhai et al., 2013), extract and active compound of
Dalbergia trichocarpa bark (Rasamiravaka et al., 2015), tea
polyphenols extracted from the leaf of Camellia sinensis L. (Yin
et al., 2015), the methanolic extract of Trigonella foenum-graecum
L. seed (Husain et al., 2015b), Syzygium aromaticum (clove)
oil (Husain et al., 2013), and Mentha piperita (peppermint)
oil (Husain et al., 2015a). In addition to targeting quorum
sensing circuits, chemical compounds such as phenylacetic acid
(Musthafa et al., 2012b), 2,5-piperazinedione (Musthafa et al.,
2012a) and meta-bromo-thiolactone (O’Loughlin et al., 2013)
as well as the hormonal therapy drug raloxifene (Ho Sui et al.,
2012) inhibited P. aeruginosa pyocyanin production and reduced
bacterial virulence in the nematode model. Other virulence
determinants, including biofilm, proteases and elastase, as well
as bacterial motility, were also suppressed by most of these
molecules. Compounds targeting the iron-regulation pathway
that alleviated P. aeruginosa-mediated killing of C. elegans were
identified from a high-throughput liquid-based chemical screen
(Kirienko et al., 2013). Recently, an anti-proliferative drug, 5-
fluorouracil, was shown to enhance the survival of P. aeruginosa-
infected C. elegans via disruption of pyoverdine biosynthesis
(Kirienko et al., 2016). Interestingly, in an independent study,
5-fluorocytosine (a 5-fluorouracil precursor) demonstrated the
ability to inhibit pyoverdine production in vivo in a mouse
model of P. aeruginosa lung infection (Imperi et al., 2013). This
compound also diminished P. aeruginosa virulence by targeting
biofilm formation and quorum-sensing phenotypes in vitro
(Ueda et al., 2009). Moreover, garlic extract also displayed anti-
quorum sensing effect against P. aeruginosa in both nematode
(Rasmussen et al., 2005) and mice models (Bjarnsholt et al.,
2005; Harjai et al., 2010). Together, these findings demonstrate
the successfully translation of the anti-virulence effect identified
in a C. elegans model in a higher organism and provides a
positive correlation between the compound activity identified in
a C. elegans model with a more complex mammalian infection
model. Through in silico drug design and model simulations, two
chemical entities were identified as inhibitors of P. aeruginosa
heme oxygenase. One of these compounds prolonged the lifespan
of infected nematodes and decreased bacterial colony forming
units in the C. elegans intestine, albeit showing poor antimicrobial
activity in vitro (Hom et al., 2013). Recently, Zhu et al. (2015)
used the C. elegans model to characterize an inhibitor of
LasB, a vital virulence factor of P. aeruginosa. Cross-sectional
transmission electron microscopy images of the C. elegans
intestine displayed less host tissue damage upon treatment with
the LasB inhibitor, suggesting that P. aeruginosa was rendered less
virulent by the compound (Zhu et al., 2015).
Staphylococcus aureus is continuously acquiring resistance
to clinically used antibiotics, underlining the need for new
anti-virulence therapeutics against this pathogen. The ability
of S. aureus to produce biofilm has complicated treatment by
blocking the antibiotics penetration of the cells encased within
the exopolysaccharide material. Hence, S. aureus biofilm and the
quorum sensing system are attractive targets for anti-virulence
therapeutics. Several natural compounds with in vitro anti-
biofilm property have been demonstrated to attenuate S. aureus
virulence in vivo in a C. elegans model. This includes essential
oils from various plants (Lee J.H. et al., 2014; Lee et al., 2014a),
red wine (Cho et al., 2015), stilbenes and the natural phenol,
resveratrol (Lee J.H. et al., 2014; Lee et al., 2014b). Moreover,
these natural products also reduced blood hemolysis caused by
S. aureus hemolysins. The colonization of S. aureus in the worm
intestine can be determined by staining the bacteria with acridine
orange dye. Using this approach, the reduction of in vivo bacterial
loads by an extract from a coral actinomycete was reported
(Bakkiyaraj and Pandian, 2010). Hamamelitannin, the active
component isolated from American witch hazel, has recently
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been shown to act as an inhibitor of the S. aureus quorum
sensing mechanism. This compound and its analogs effectively
improved the susceptibility of S. aureus biofilms to multiple
antibiotics treatment both in vitro and in vivo (C. elegans and
mouse infection models) (Brackman et al., 2016).
The uracil-auxotroph E. coli strain OP50 is routinely used
as the laboratory-based food source for C. elegans, however,
some pathogenic E. coli strains are lethal on worms. E. coli
O157:H7 is a toxin-producing enterohemorrhagic strain with
noteworthy medical implications. Broccoli extract and its
associated flavonoid compounds were able to impede the
virulence of this E. coli strain in the nematode model by inhibiting
a number of vital virulence genes as well as the swarming motility
of E. coli O157:H7 (Lee et al., 2011). Screening a collection
of plant secondary metabolites for anti-biofilm activity against
E. coli O157:H7 also identified several coumarin derivatives that
were subsequently shown to suppress pathogen virulence in vivo
in the C. elegans infection system (Lee J.H. et al., 2014). Lavigne
et al. (2008) utilized the C. elegans model to compare virulence
of E. coli strains isolated from urine samples of individuals who
consumed either cranberry or placebo capsules. E. coli strains
from patients who took regular cranberry capsules displayed
reduced adherence in vitro and delayed killing of C. elegans
(Lavigne et al., 2008). Apart from this, the C. elegans model has
also been used to screen for anti-virulence compounds from a
collection of∼250 marine sponge associated bacterial extracts for
their ability to rescue the nematodes from a Vibrio alginolyticus
infection (Durai et al., 2013). The active ingredients isolated from
plants and seawater bacteria inhibited Vibrio cholerae biofilm
production and reduced V. cholerae virulence in the killing
of nematodes (Kim H.I. et al., 2015; Rajalaxmi et al., 2016).
Natural compounds that affected the virulence of Gram-positive
Clostridium difficile (Yun et al., 2015) and Listeria monocytogenes
(Silva et al., 2015; Sivaranjani et al., 2016) have also been recently
described.
Compounds Activating/Modulating Host
Immune Responses
Despite lacking an adaptive immune system, C. elegans
is still capable of activating protective mechanisms when
confronted with pathogenic microorganisms in its natural
habitat. The worms mount a complex and non-specific ancestral
immune response, involving the activation of multiple signal
transduction pathways and the secretion of immune effector
molecules (Ermolaeva and Schumacher, 2014). This makes
the identification of compounds targeting the host innate
immune system possible using the C. elegans-based infection
system. Following the initial high-throughput antimicrobial
screen by Moy et al. (2009), the compound RPW-24 was
shown to extend the lifespan of P. aeruginosa-infected worms
without compromising bacterial integrity (Pukkila-Worley et al.,
2012). By employing various approaches including microarray
analysis using the readily available Affymetrix full-genome
C. elegans GeneChip, as well as pathway elucidation studies using
transgenic GFP reporter and mutant worms, the effect of the
compound on host immunity was further characterized. RPW-
24 was found to protect the worms from bacterial infection
by inducing the p38 MAP kinase pathway-mediated response
and the transcription factor ATF-7, suggesting the utility of the
C. elegans model to discover novel strategies effective in treating
bacterial infections (Pukkila-Worley et al., 2012). The extract
from Swietenia macrophylla seeds promoted the survival of
P. aeruginosa-challenged nematodes by boosting the expression
of a C. elegans lysozyme encoding gene (lys-7) as observed by
increasing fluorescence intensity in lys-7::GFP transgenic worms
(Dharmalingam et al., 2012). Similarly, the nematodes subjected
to P. aeruginosa infection were rescued by supplementation
with dietary selenium. Selenite treatment did not interfere
with bacterial quorum sensing and virulence, but elevated the
transcript levels of host putative antimicrobial genes such as lys-1,
spp-1, and abf-1. It was also demonstrated that the pathogen-
resistant phenotype conferred by selenite requires the presence
of a functional SKN-1 in C. elegans (Li et al., 2014).
From the C. elegans–S. aureus anti-infective screen discussed
in Section “Compounds with In vivo Antimicrobial Activity,”
our group identified an extract from a local plant, Orthosiphon
stamineus, as a potential immunomodulatory drug that enhanced
host tolerance toward a deadly S. aureus infection. This extract
was not antimicrobial per se and is non-toxic to the C. elegans
model. Expression of the host lys-7 antimicrobial gene in
untreated worms was suppressed after 24 and 48 h exposure
to S. aureus. This suppression is mediated by the pathogen’s
ability to alter the host defense mechanism, particularly the
host antimicrobial response. As noted through observations of
a fluorescing transgenic strain infected by S. aureus, the down-
regulation of lys-7 was restored in the presence of O. stamineus
extract. Analysis using a loss-of-function C. elegans mutant
established that the protective role of this extract is mediated
via the conserved p38 MAPK and daf-2/daf-16 insulin-like
signaling pathways. qRT-PCR analysis of the host PMK-1 and
DAF-16-regulated antimicrobial genes confirmed a significant
positive modulation of these genes in S. aureus-infected worms
exposed to O. stamineus extract. Further studies also revealed
eupatorin as the major bioactive ingredient that contributed
to the immunomodulation effect of O. stamineus (Kong et al.,
2014a). In a separate study, O. stamineus extract also modulated
the cellular immune response in vitro (Alshawsh et al., 2012).
Similarly, the natural polyphenols isolated from Magnolia plant
species, honokiol and magnolol, promoted a cellular immune
response and slowed down C. elegans killing by S. aureus (Choi
et al., 2015).
Host-directed immunomodulators offer a number of
potential advantages over antimicrobial drugs. Targeting the
host immunity in combating pathogen infection is an appealing
approach as the stimulation or modulation of host immune
function may promote resistance against a diverse array of
pathogens, forming the basis of broad spectrum therapeutics to
treat infections (Nijnik, 2013). Additionally, it may lower the
risk of selection toward treatment resistance. The water-soluble
cranberry extract was reported to up-regulate the expression
of C. elegans innate immune genes and confer protection
against various major pathogens, namely V. cholerae, E. coli
O157:H7, P. aeruginosa, Salmonella typhimurium, S. aureus,
and E. faecalis (Dinh et al., 2014). Specifically, the protective
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effect of this extract against V. cholerae is dependent on the
p38 MAPK signaling pathway. The wide spectrum activity
of other immunomodulatory compounds has also been seen
for the alkaloid compounds harmane and colistin. Harmane
promoted survival in nematodes infected by both Gram positive
and Gram negative pathogens, including E. coli strain EDL933,
S. typhimurium, P. aeruginosa, and E. faecalis (Jakobsen et al.,
2013). Cai et al. (2014) developed a C. elegans – based chemical
screen for the discovery of immune-inductive drugs using
the F35E12.5::gfp transgenic strain and they identified the
antibiotic colistin as a potential hit. The nematodes pre-treated
with colistin were also resistant against Yersinia pestis and
P. aeruginosa infections (Cai et al., 2014).
Concomitantly, some anti-infectives may exhibit both anti-
virulence and immunomodulatory effects. The water extract
of red seaweed Chondrus crispus exerted dual anti-infective
effects by simultaneously disabling the virulence of P. aeruginosa
and elevating host immunity to combat pathogen infection.
C. crispus down-regulated mRNA levels of quorum sensing
and virulence-related genes and retarded the secretion of
P. aeruginosa virulence factors such as protease, elastase,
pyocyanin, siderophore, hydrogen cyanide, and biofilm (Liu
et al., 2013). Furthermore, the protective effect of C. crispus
extract was diminished in selected C. elegans mutants (pmk-
1, daf-2, daf-16, or skn-1), implying that the effect from
the host perspective is mediated via the highly conserved
immune pathways. Likewise, concurrent virulence inhibitory
and immunostimulatory effects have also been observed in
other seaweed-related natural products, including Tasco R©, a
commercially available animal feed supplement made from the
brown seaweed Ascophyllum nodosum (Kandasamy et al., 2012)
and another red seaweed species Sarcodiotheca gaudichaudii
(Kulshreshtha et al., 2016). Both, S. gaudichaudii and C. crispus
extracts disarmed the pathogenicity of Salmonella enteritidis by
reducing biofilm formation, swimming and swarming motility
and down-regulating expression of virulence and quorum
sensing genes in S. enteritidis. These extracts also reduced
the intestinal bacterial load in C. elegans by promoting the
expression of host immune response genes encoding lectin-
family, saponin-like and antibacterial proteins (Kulshreshtha
et al., 2016). Whilst no direct evidence of seaweed extract exerting
an immunomodulatory effect on animal infection-directed
immune responses, is available, Luo et al. (2015) demonstrated
that seaweed polysaccharide was immunomodulatory in a cell-
culture based assay as well as in a mouse tumor model. The
seaweed polysaccharide enhanced the tumor immune response
by increasing the number of tumor-infiltrating immune-related
cells in the murine lymphoma model. The various experimental
procedures used to scrutinize the mode of action of a compound
targeting bacterial virulence and/or host immunity are outlined
in Figure 2.
Although, therapeutics that involve the immune system can
be broad spectrum against a wide variety of infecting agents,
overstimulation or dysregulation can lead to potential harmful
side effects such as uncontrolled inflammatory response that
may cause tissue damage or even worse, immunosuppression
that may result in the shutdown of the entire immune system.
For example, the immunomodulatory drug RPW-24 generally
induced a C. elegans detoxification pathway and triggered
C. elegans aversion behavior under an uninfected condition.
Concurrently, the basal lifespan of the uninfected population was
also shortened and the development of C. elegans larva was halted
upon exposure to this compound (Pukkila-Worley et al., 2012).
Therefore, the mechanism of immunostimulatory molecules
must be carefully investigated to maximize the beneficial effect
and at the same time minimizing the possible toxic effects.
Furthermore, the precise mode of drug administration (e.g.,
prophylactic or during infection) should also be determined to
ensure effective treatment.
C. elegans: A POTENTIAL REPERTOIRE
OF ANTIMICROBIAL PROTEINS AND
PEPTIDES (APPs)
In C. elegans, many of the pathogens are ingested and
survive the passage through the worm grinder to establish an
infection in the intestinal lumen, including Serratia marcescens
(Schulenburg and Ewbank, 2004), S. aureus (Sifri et al., 2003),
and P. aeruginosa (Tan et al., 1999). Certain pathogens can
stably colonize the intestinal tract and eventually overwhelm the
worm, leading to death. Such infections have been demonstrated
for S. typhimurium (Aballay et al., 2000) and E. faecalis
(Garsin et al., 2001). Similar to the intestine, but to a lesser
extent, the epidermis that covers the worm external body
surface is also vulnerable to pathogen attack. Some bacteria
like Microbacterium nematophilum or Leucobacter spp. Verde
adhere to the cuticle, causing swelling of the hypodermal tissue
(Hodgkin et al., 2000, 2013) whilst the fungus Drechmeria
coniospora adheres to the region of the mouth and vulva,
and penetrates through the epidermis (Jansson, 1994). Yang
et al. (2005) also demonstrated that the nematophagous fungus
Lecanicillium psalliotae secretes serine protease that facilitates
mycelia penetration and degradation of worm cuticle (Yang et al.,
2005).
With the aid of transcriptomics, it is now clear that infected
worms are able to mount an inducible defense system, involving
the activation of specific signaling pathways which lead to
the release of immune molecules, including APPs (Couillault
et al., 2004; O’Rourke et al., 2006; Shapira et al., 2006; Troemel
et al., 2006; Zugasti and Ewbank, 2009; Gravato-Nobre et al.,
2016). As opposed to conventional antibiotics, many APPs
directly act on the membrane of the pathogen and thus, the
development of microbial resistance by gene mutation is less
likely (Peschel and Sahl, 2006). In some cases, APPs may possess
immunomodulatory functions (Lai and Gallo, 2009; Nijnik and
Hancock, 2009; Afacan et al., 2012), including (i) reduction in
the levels of pro-inflammatory cytokines, (ii) modulation of the
expression of chemokines, reactive oxygen species and reactive
nitrogen cytokines, (iii) stimulation of angiogenesis, (iv) wound
healing, and (v) leukocyte and macrophage differentiation. Up till
now, a diverse array of putative APPs has been identified based on
their induced expression upon infection or sequence similarities
(Kato et al., 2002; Pujol et al., 2008), however, how these different
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FIGURE 2 | Overview of the general experimental approaches used to characterize an anti-infective candidate. A potential anti-infective compound that
does not directly target bacterial growth can either impair pathogen virulence and/or enhance/modulate host immune responses. Various strategies from both
pathogen and host perspectives can be employed to further characterize the molecular mechanism(s) of the compound of interest. Whole-genome transcriptome
profiles of the compound-treated pathogen or host can be generated to study the effect of the compound. To assess the effect on bacterial virulence, qualitative and
quantitative biochemical tests as well as biofilm production and quorum sensing assays can be performed. Bacterial mutants are useful for target identification while
GFP-expressing bacteria may assist in visualization of in vivo bacterial colonization. Electron microscopy can be used to observe the formation of biofilm or bacterial
structures (e.g., flagella). In silico molecular docking provides a clue of the possible binding interference between a bacterial protein and the compound of interest.
From the host perspective, the live bacteria can be recovered from the C. elegans intestine and enumerated. The readily available transgenic mutant strains are
useful for host target identification and pathway elucidation.
APPs act cooperatively has not yet been characterized. For this
review, we only focus on the representative families of APPs that
have been documented to exhibit in vitro antimicrobial activity
at the peptide/protein level. Figure 3 depicts the tissue-specific
induction of APPs in C. elegans.
Caenopores
Examination of the worm’s genome led to the discovery of
saposin-like peptides/proteins (SPPs) characterized by an α-helix
bundle stabilized by three unique disulphide bonds (Bruhn,
2005). Alternatively, they are named as caenopores owing to
their structural and functional resemblance with amoebapores as
they consist of a secretory signal peptide followed by saposin-like
domain (Roeder et al., 2010). Given that most spp gene expression
is regulated by the intestine specific transcription factor ELT-
2, it is likely that caenopores are exclusively expressed in the
intestine (Hoeckendorf and Leippe, 2012; Hoeckendorf et al.,
2012). The direct role for caenopores in the innate immune
response of C. elegans was first reported in Banyai and Patthy
(1998) when the antibacterial effect of recombinant SPP-1 was
observed on E. coli. Like amoebapores, SPP-5 was shown to
display pore-forming activity and kill bacteria by permeabilising
the cytoplasmic membrane (Roeder et al., 2010). A detailed
examination of three-dimensional structure revealed that SPP-5
has five amphiphatic helices, connected by three disulfide bonds
arranged like a folded leaf, which is the signature of the SAPLIP
family (Mysliwy et al., 2010). It was worth noting that this was the
first and only representative structure solved for C. elegans APPs.
The molecular mechanism underlying pore formation however
remains unclear.
Antibacterial Factor (ABF)
Peptides/Proteins
A total of six ASABF (Ascaris suum antibacterial factor)
homologs or best known as antibacterial factor (ABF-1 to ABF-
6) peptides/proteins have been identified in C. elegans. ASABF is
a cysteine-rich microbicidal factor that was first discovered in the
body fluid of the nematode A. suum (Kato and Komatsu, 1996).
It is possible that ABFs are also part of the C. elegans defense
mechanism as exposure to pathogens led to the up-regulation of
abf genes (Alegado et al., 2003; Alper et al., 2007; Means et al.,
2009). By means of RNAi-mediated gene silencing, the functional
significance of ABFs was further characterized. Silencing one of
these genes, abf-2, led to increased bacterial load in the intestinal
lumen (Alegado et al., 2003). It is well-established that expression
of abf genes is localized primarily at the site of contact with
bacteria, i.e., in the digestive tract (Alper et al., 2007). To date,
only recombinant ABF-2 is known to display broad-spectrum
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FIGURE 3 | Induction of APPs in C. elegans. When C. elegans encounters
a single pathogen, it will secrete a mixture of APPs as part of its protective
mechanism, specifically (A) caenopores/saposin-like proteins (SPPs),
antibacterial factor proteins (ABFs) and invertebrate lysozymes (ILYSs) in the
digestive tract, and (B) neuropeptide-like proteins (NLPs) at the epidermis.
The dashed line arrow denotes the route of infection.
antimicrobial activity, with the greatest effect observed toward
Gram-positive bacteria (Kato et al., 2002). The precise role(s) of
other members of this family are still unclear and required further
analysis.
Invertebrate Lysozymes (ILYS)
Caenorhabditis elegans harbors protist-type (lys-1 to lys-10) and
invertebrate type (ilys-1 to ilys-6) lysozyme encoding genes
(Schulenburg and Boehnisch, 2008; Tarr, 2012). Representative
members of the latter are up-regulated upon exposure to various
pathogen insults (Irazoqui et al., 2010), suggesting possible roles
involved in host defense. Studies using recombinant ILYS-3
have reported that the protein displays lytic activity against
the Gram-positive Micrococcus luteus and M. nematophilum.
It is known that invertebrate lysozymes are able to cleave the
isopeptide bonds established between D-glutamate and L-Lysine
present in peptidoglycans (Tarr, 2012; Van Herreweghe and
Michiels, 2012). The importance of invertebrate lysozymes for
host defense was recently confirmed when Gravato-Nobre et al.
(2016) reported that disruption of ilys-3 renders the mutant
worms more susceptible to M. nematophilum. The investigators
also elegantly showed that ILYS-3 is primarily produced in
the C. elegans digestive tract (Gravato-Nobre et al., 2016). For
additional information of the protist-type lysozymes, readers are
referred to previous reviews (Schulenburg and Boehnisch, 2008;
Ewbank and Zugasti, 2011).
Neuropeptide-Like Peptides/Proteins
(NLPs)
In C. elegans, most of the neuropeptide-like peptides/proteins
(nlp) genes were named as such because of their limited sequence
similarity with YGGXamide neuropeptide genes, sharing the
YGGWG and YGGYG motifs (Nathoo et al., 2001). These
genes form “the nlp-29 cluster” which comprises nlp-27 to
nlp-31 and the adjacent gene nlp-34 on chromosome V
(Couillault et al., 2004; Pujol et al., 2008). Upon exposure to the
nematode-trapping fungus Monacrosporium haptotylum, several
nlp genes were induced in infected worms (Fekete et al., 2008).
Overexpression of these genes enhanced worm resistance to
D. coniospora infection, further validating their contribution to
in vivo host defense (Pujol et al., 2008). Couillault et al. (2004)
demonstrated that the 53-amino-acid synthetic NLP-31 has
potent antimicrobial activity against fungi and several bacteria.
Utilizing transgenic worms expressing GFP under the control of
the nlp-31 promoter, these investigators also demonstrated that
this gene is exclusively expressed in the hypodermis. Recent work
from our group has proposed an immunomodulatory role for
NLP-31 as the peptide regulated the expression of inflammatory
cytokines in B. pseudomallei-infected macrophage cells. Several
lines of evidence suggest that it employs a mechanism that does
not involve membrane permeabilisation, but instead interact with
cytoplasmic macromolecules to interfere with the viability of B.
pseudomallei (Lim et al., 2016).
CONCLUDING REMARKS
Active research on the development of anti-infective therapeutics
that target bacterial virulence and/or host immune response
using a C. elegans host model indicates a paradigm shift in
the understanding of the host–pathogen interface. The existence
of notable similarities at the molecular and cellular levels
between nematode and higher vertebrates opens a path toward
the discovery of novel therapeutics for human infections that
might exhibit superior function over conventional antibiotics.
The findings generated in the simple nematode model provide
insights into the modulation of bacterial virulence and host
immunity to fight infectious diseases and can readily be translated
to higher organisms. Despite numerous efforts to tackle the
spread of antimicrobial resistance, bacteria continue to show
reduced susceptibility toward antibiotics over time and the rate
of new drug discovery is declining rapidly. Developing alternative
anti-infectives that do not affect bacterial cell viability hold great
potential to compensate for this significant health care challenge.
In addition, C. elegans APPs also provide a parallel opportunity
to uncover host candidates for drug discovery.
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